- BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma studyBeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. T…Endpoints · 28d ago↗ source
- House China panel probes Bristol Myers, Pfizer on use of trial sitesA congressional committee has opened an inquiry into Bristol Myers Squibb and Pfizer's use of clinical trial sites in China, including facilities that the committee's chairman said are affiliated w…Endpoints · 28d ago↗ source
- STAT+: Even with MAHA, Trump administration has gone soft on alcoholA STAT investigation has found that the Trump administration has downplayed alcohol’s risks and actively derailed efforts to understand and prevent drinking-related harms.